UNSPSC 51171710: Alosetron

This classification denotes a 5-ht3 receptor antagonist with the molecular formula C17H18N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13Z9HTH115, chemically known as 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1h-imidazol-4-yl)methyl)-1h-pyrido(4,3-b)indol-1-one but generally known as alosetron, which bears US NIH Compound Identifier 2099. Alosetron comes in base and hydrochloride forms. European Medicines Agency schedules Alosetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05358MIG.

UNSPSC 51171710 Alosetron, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities involve offender drug testing services, direct-to-manufacturer pharmacy initiatives, and generic multi-source pharmaceutical supply agreements — none of which concern alosetron specifically or gastrointestinal pharmaceutical procurement in general. The code shows little relevant recent activity; the mismatch suggests either misclassification of these opportunities or dormancy in alosetron-specific state and local purchasing at the time these solicitations were posted.

The three posted opportunities span different issuing bodies and geographies: Collin County Community Supervision and Corrections Department (Texas) issued an RFP for offender specimen collection and drug testing services due July 23, 2026; the Texas Health and Human Services Commission posted an RFI on direct-to-manufacturer prescription programs with a response deadline of April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance administered by the Minnesota Department of Administration issued an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with participation from participating state and local facilities including Oregon. None of these solicitations target alosetron or single-drug pharmaceutical procurement. Business development professionals should verify whether opportunities under this code reflect actual alosetron purchasing by state and local health systems, correctional facilities, or insurance programs before committing pursuit resources.